Pan-Canadian Pharmaceutical Alliance (pCPA) has posted the IBM Report on its website
The much anticipated IBM report (entitled “Pan Canadian Drugs Negotiation Report”) has now been posted on the pCPA website.
The objectives of the IBM engagement include:
- Recommending options for the development of a permanent model that will facilitate negotiations for brand name drugs and approaches to achieving better value for money for generic drugs. The options had to consider feasibility of implementation, including joint versus separate governance and administration of the two initiatives.
- Performing a detailed analysis of the current process, regulatory barriers within each jurisdiction, operational considerations and resource requirements.
The 94 page report details the study’s approach, stakeholder feedback, results of an environmental scan, and pCPA process and governance considerations. The report also outlines numerous recommendations for consideration. One recommendation that has already been implemented is the name change from Pan-Canadian Pricing Alliance to Pan-Canadian Pharmaceutical Alliance. It remains to be seen how many other recommendations the PCPA will implement over the comings weeks/months.
For more information regarding the IBM report, please visit the pCPA website.